Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer
- PMID:10368200
- DOI: 10.1046/j.1464-410x.1999.00028.x
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer
Abstract
Objective: To determine the endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of Zoladextrade mark (goserelin acetate, Zeneca Pharmaceuticals, Wilmington, Delaware, USA), a luteinizing hormone-releasing hormone agonist analogue, when administration was extended from every 12 weeks to every 13 weeks in patients with advanced prostate cancer.
Patients and methods: Between July 1995 and May 1996, 59 patients with either locally advanced (T3 or T4) or metastatic prostate cancer were enrolled in an open-label, multicentre trial. Primary efficacy endpoints were testosterone measurements, and assessments of prostate specific antigen (PSA) response, subjective and objective response. Quality of life (QoL) was a secondary efficacy endpoint.
Results: Mean testosterone concentrations decreased to < 0.3 microgram/L by week 4 and remained so for the duration of treatment. There were no statistically significant differences in mean testosterone levels between weeks 12 and 13, or weeks 25 and 26. Serum testosterone suppression was adequate in all 58 evaluable patients at week 13, and 51 of 52 (98%) patients at week 26. Of the 58 evaluable patients, 52 (90%) had a PSA response. A subjective response was recorded for six of 11 evaluable patients. Of 58 patients evaluable for objective response, 46 (79%) had a partial response, three (5%) had stable disease and nine (16%) had objective progression. Except for a significant (P=0.014) decrease in overall sexual interest, QoL was unchanged during therapy. The most common side-effects, regardless of causality, were hot flushes (67%), pain (31%) and pelvic pain (22%). Mild injection-site complaints occurred with only three of 221 (1.4%) depot injections.
Conclusions: Zoladextrade mark 10.8-mg depot, administered every 13 weeks to patients with advanced prostatic cancer, is well tolerated, provides adequate suppression of serum testosterone and produces PSA, subjective and objective responses.
Similar articles
- 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.Fontana D, Mari M, Martinelli A, Boccafoschi C, Magno C, Turriziani M, Maymone SS, Cunico SC, Zanollo A, Montagna G, Frongia M, Jacobellis U.Fontana D, et al.Urol Int. 2003;70(4):316-20. doi: 10.1159/000070142.Urol Int. 2003.PMID:12740498Clinical Trial.
- Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.Sharifi R, Knoll LD, Smith J, Kramolowsky E.Sharifi R, et al.Urology. 1998 Feb;51(2):271-6. doi: 10.1016/s0090-4295(97)00500-1.Urology. 1998.PMID:9495710Clinical Trial.
- A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.Debruyne FM, Dijkman GA, Lee DC, Witjes WP, del Moral F, Karthaus HF, van der Mejden AP, Plasman JW, Pull HC, Kums JJ, Idema JG, Hoefakker JW, Heijbroek RP, Kil PJ, Khoe GS.Debruyne FM, et al.J Urol. 1996 Apr;155(4):1352-4.J Urol. 1996.PMID:8632572Clinical Trial.
- [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].Tsukagoshi S.Tsukagoshi S.Gan To Kagaku Ryoho. 2002 Sep;29(9):1675-87.Gan To Kagaku Ryoho. 2002.PMID:12355959Review.Japanese.
- Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.Goldspiel BR, Kohler DR.Goldspiel BR, et al.DICP. 1991 Jul-Aug;25(7-8):796-804. doi: 10.1177/106002809102500716.DICP. 1991.PMID:1835221Review.
Cited by
- Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.Crawford ED, Phillips JM.Crawford ED, et al.Cancer Manag Res. 2011;3:201-9. doi: 10.2147/CMR.S12700. Epub 2011 Jul 20.Cancer Manag Res. 2011.PMID:21847353Free PMC article.
- Mechanism of hot flashes.Vilar-González S, Pérez-Rozos A, Cabanillas-Farpón R.Vilar-González S, et al.Clin Transl Oncol. 2011 Mar;13(3):143-7. doi: 10.1007/s12094-011-0633-x.Clin Transl Oncol. 2011.PMID:21421458Review.
- Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.Lu YS, Wong A, Kim HJ.Lu YS, et al.Front Oncol. 2021 Sep 14;11:700722. doi: 10.3389/fonc.2021.700722. eCollection 2021.Front Oncol. 2021.PMID:34595110Free PMC article.Review.
- Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.Chen N, Wang Z, Chen M, Ma Q, He Y, Wang Y, Li X, Qiu M, Shi L, Zhu S, Xie Q, Liu X, Shi B, Lin G, Yang W, Liao Y, Zhang H, Wang S, Li J, Wang S, Dong L, Chen H, Lu J, Cheng Y, Zhang X, Ma L, Zhou L, Wang H, Li S, Ye D.Chen N, et al.Cancer Biol Med. 2024 Feb 5;20(12):1047-59. doi: 10.20892/j.issn.2095-3941.2023.0335.Cancer Biol Med. 2024.PMID:38318809Free PMC article.
- Clinical pharmacokinetics of goserelin.Cockshott ID.Cockshott ID.Clin Pharmacokinet. 2000 Jul;39(1):27-48. doi: 10.2165/00003088-200039010-00003.Clin Pharmacokinet. 2000.PMID:10926349Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous